However, despite constitutive engagement of the DDI2-NRF1 pathway, we were able to select and expand DDI2 or NRF1-deficient MM monoclones to the same efficacy as with control populations, suggesting that neither DDI2 nor NRF1 are essential for MM survival in unstressed conditions. This evidence concerns the gene DDI2 and Miyoshi myopathy.